Ilex Medical – the stock flew almost 5% against the background of the reports

by time news

The gross profit margin for the quarter was 45.7% compared to 30.9% in the corresponding quarter last year; The gross profit margin in the first nine months was 36.6% compared to 31.2% last year.

EBITDA in the quarter increased by 72% compared to last year and amounted to NIS 118 million. EBITDA in the first nine months of the year increased by approximately 62% compared to last year and amounted to approximately NIS 235 million compared to NIS 186 million in all of 2020.

The net profit attributed to shareholders in the quarter increased by 69% compared to last year and amounted to NIS 84 million. The net profit attributable to shareholders increased in the first nine months of the year by approximately 71% compared to last year and amounted to approximately NIS 155 million.

Tami Galili, CEO of Ilex Medical: “The Corona epidemic accelerated the company’s growth and at the same time allowed us to develop new growth engines in the field of medical equipment, bidding in box office auctions and investing in innovative start-ups. We continue to present record results with an excellent quarter indicating growth in all parameters.” , In which Ilex has responded to this epidemic in a number of areas, including the Laboratory in Airport City. “New growth engines, we announced an investment agreement with Starget Pharma, under which Ilex will acquire up to 33% of the company, which specializes in cancer diagnosis and treatment, for a maximum of $ 10 million.”

Emphasis on results in the consolidated

Net revenues in the quarter increased by 4% and amounted to NIS 310 million, compared with NIS 297.5 million last year. In dollar terms, growth was 10%.

Gross profit for the quarter increased by 54% and amounted to NIS 141.6 million, compared with NIS 91.8 million in the corresponding quarter last year. The gross profit margin was 45.7% compared to 30.9% in the corresponding quarter last year.

Operating profit for the quarter increased by approximately 76% and amounted to approximately NIS 106.9 million, compared with approximately NIS 60.6 million last year.

EBITDA in the quarter increased by approximately 72% and amounted to approximately NIS 118.1 million, compared with approximately NIS 68.6 million last year.

The net profit attributable to the company’s shareholders in the quarter increased by approximately 69% and amounted to approximately NIS 84 million, compared with approximately NIS 49.6 million in the corresponding quarter last year.

Main emphases for the company’s operating segments

Ilex – the diagnostics sector

Revenues in the quarter increased by 78% and amounted to NIS 229.1 million, compared with NIS 128.7 million in the corresponding quarter last year. In dollar terms, there was an increase of about 88%. The increase in sales is mainly due to the response given by the Ilex Group in dealing with the Corona virus epidemic.

Gross profit in the quarter increased almost threefold and amounted to NIS 121.9 million, compared with NIS 42.6 million in the corresponding quarter last year. The gross profit margin was 53.2% compared to 33.1% in the corresponding quarter. The increase is mainly due to differences in the mix of sales and operations of the Corona Laboratory, as well as improved processes and streamlining of its operations.

Operating profit (excluding other income) increased almost fourfold in the quarter and amounted to NIS 105.2 million, compared with NIS 28.1 million last year.

EBITDA in the quarter increased 3.5 times and amounted to NIS 110.6 million, compared with NIS 31.6 million in the corresponding quarter last year.

Medtechnica – Medical Equipment Sector

Revenues in the quarter amounted to NIS 76.4 million, compared with NIS 129.5 million in the corresponding quarter last year. The decrease is mainly due to the effect of the corona epidemic on sales in the corresponding period last year.

Gross profit amounted to NIS 18.1 million, compared with NIS 28.2 million in the corresponding quarter last year. The gross profit margin was 23.7% compared to 21.8% last year.

Operating profit (excluding other income) amounted to NIS 2.8 million in the quarter, compared with NIS 14 million in the corresponding quarter last year.

EBITDA in the quarter amounted to NIS 7.8 million, compared with NIS 18.7 million in the corresponding quarter last year.

Plate – The Soul Instruments Sector

Revenues in the quarter amounted to NIS 3.9 million, compared with NIS 38.3 million in the corresponding quarter last year. The decline is due to high demand for respirators in the same period last year as a result of the corona plague.

Gross profit for the quarter amounted to NIS 1.6 million, compared with NIS 20.7 million in the corresponding quarter last year. The gross profit margin was 42.0% compared to 54.0% in the corresponding quarter last year.

The company reports an operating loss of NIS 0.5 million, compared with an operating profit of NIS 18.1 million in the corresponding quarter last year.

.

You may also like

Leave a Comment